Clément Gakuba

Clément Gakuba

Auto-generated profile, based on publicly available information

Clément Gakuba

Department of Anesthesiology and Critical Care Normandie Univ, UNICAEN, CHU de Caen Caen France

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Critical Care Medicine
Verified
Journal Article
Closed access
CGClement Gakuba
Clement Gakuba
CBCharlene Le Barbey
Charlene Le Barbey
ASAlexandre Sar
Alexandre Sar
GBGregory Bonnet
Gregory Bonnet
DCDamiano Cerasuolo
Damiano Cerasuolo
JMJean-Denis Moyer
Jean-Denis Moyer
OBJECTIVES: To evaluate the capacity of ChatGPT, a widely accessible and uniquely popular artificial intelligence-based chatbot, in predicting the 6-month outcome following moderate-to-severe traumatic brain injury (TBI). DESIGN: Single-center observational retrospective study. SETTING: Data are from a neuro-ICU from a level 1 trauma center. PATIENTS: All TBI patients admitted to ICU between September 2021 and October 2022 were included in a prospective database. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Based on anonymized clinical, imaging, and biological information available at the patients’ hospital admission and extracted from the database, clinical vignettes were retrospectively submitted to ChatGPT for prediction of patients’ outcomes. The predictions of two intensivists (one neurointensivist and one non-neurointensivist) both from another level 1 trauma center (Beaujon Hospital), were also collected as was the International Mission on Prognosis and Analysis of Clinical Trials in Traumatic Brain Injury (IMPACT) scoring. Each intensivist, as well as ChatGPT, made their prognostic evaluations independently, without knowledge of the others’ predictions and of the patients’ actual management and outcome. Both the intensivists and ChatGPT were given access to the exact same set of information. The main outcome was a 6-month-functional status dichotomized into favorable (Glasgow Outcome Scale Extended [GOSE] ≥ 5) versus poor (GOSE < 5). Prediction of intracranial hypertension management, pulmonary infectious risk, and removal of life-sustaining therapies was also investigated as secondary outcomes. Eighty consecutive moderate-to-severe TBI patients were included. For the 6-month outcome prognosis, area under the receiver operating characteristic curve (AUC-ROC) for ChatGPT, the neurointensivist, the non-neurointensivist, and IMPACT were, respectively, 0.62 (0.50–0.74), 0.70 (0.59–0.82), 0.71 (0.59–0.82), and 0.81 (0.72–0.91). ChatGPT had the highest sensitivity (100%), but the lowest specificity (26%). For secondary outcomes, ChatGPT’s prognoses were generally less accurate than clinicians’ prognoses, with lower AUC values for most outcomes. CONCLUSIONS: This study does not support the use of ChatGPT for prediction of outcomes after TBI.

6 May 2024 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Open access
FVFranck Verdonk
Franck Verdonk
PLPierre Lambert
Pierre Lambert
CGClément Gakuba
Clément Gakuba
ANAnais Charles Nelson
Anais Charles Nelson
TLThomas Lescot
Thomas Lescot
JMJean Mantz
Jean Mantz
Preventive anesthetic impact on the high rates of postoperative neurocognitive disorders in elderly patients is debated. The Prevention of postOperative Cognitive dysfunction by Ketamine (POCK) study aimed to assess the effect of ketamine on this condition. This is a multicenter, randomized, double-blind, interventional study. Patients ≥60 years undergoing major orthopedic surgery were randomly assigned in a 1:1 ratio to receive preoperative ketamine 0.5 mg/kg as an intravenous bolus (n = 152) or placebo (n = 149) in random blocks stratified according to the study site, preoperative cognitive status and age. The primary outcome was the proportion of objective delayed neurocognitive recovery (dNR) defined as a decline of one or more neuropsychological assessment standard deviations on postoperative day 7. Secondary outcomes included a three-month incidence of objective postoperative neurocognitive disorder (POND), as well as delirium, anxiety, and symptoms of depression seven days and three months after surgery. Among 301 patients included, 292 (97%) completed the trial. Objective dNR occurred in 50 (38.8%) patients in the ketamine group and 54 (40.9%) patients in the placebo group (OR [95% CI] 0.92 [0.56;1.51], p = 0.73) on postoperative day 7. Incidence of objective POND three months after surgery did not differ significantly between the two groups nor did incidence of delirium, anxiety, apathy, and fatigue. Symptoms of depression were less frequent in the ketamine group three months after surgery (OR [95%CI] 0.34 [0.13-0.86]). A single preoperative bolus of intravenous ketamine does not prevent the occurrence of dNR or POND in elderly patients scheduled for major orthopedic surgery. (Clinicaltrials.gov NCT02892916.).

1 June 2021 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
CGClement Gakuba
Clement Gakuba
ASAlexandre Sar
Alexandre Sar
IGIsabelle Gaborieau
Isabelle Gaborieau
JHJean-Luc Hanouz
Jean-Luc Hanouz
PVPierre Verger
Pierre Verger

1 October 2021 in Anaesthesia Critical Care & Pain Medicine
Verified
Journal Article
Closed access
JBJennifer Bourgès
Jennifer Bourgès
CGClément Gakuba
Clément Gakuba
FPFelipe Plass
Felipe Plass
JGJean-Louis Gérard
Jean-Louis Gérard
TSThérèse Simonet
Thérèse Simonet
JHJean-Luc Hanouz
Jean-Luc Hanouz

1 June 2024 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
CGClement Gakuba
Clement Gakuba
ADAlexandru-Daniel Dumitrascu
Alexandru-Daniel Dumitrascu
PMPierre-Emmanuel Marsan
Pierre-Emmanuel Marsan
DLDamien Legallois
Damien Legallois
JHJean-Luc Hanouz
Jean-Luc Hanouz
DCDamiano Cerasuolo
Damiano Cerasuolo
Multimers of von Willebrand factor play a critical role in various processes inducing morbidity and mortality in cardiovascular-risk patients. With the ability to reduce von Willebrand factor multimers, N-acetylcysteine (NAC) could reduce mortality in patients undergoing coronary catheterization or cardiac surgery. However, its impact in perioperative period has never been studied so far in regard of its potential cardiovascular benefits. Then, 4 databases were searched for randomized controlled trials that compared in-hospital mortality between an experimental group, with NAC, and a control group without NAC, in patients undergoing coronary catheterization or cardiac surgery. The primary efficacy outcome was in-hospital mortality. Secondary outcomes were the occurrence of thrombotic events, major cardiovascular events, myocardial infarction, and contrast-induced nephropathy. The safety outcome was occurrence of hemorrhagic events. Nineteen studies totaling 3718 patients were included. Pooled analysis demonstrated a reduction of in-hospital mortality associated with NAC: odds ratio, 0.60; 95% confidence interval, 0.39–0.92; P = 0.02. The occurrence of secondary outcomes was not significantly reduced with NAC except for contrast-induced nephropathy. No difference was reported for hemorrhagic events. Subgroup analyses revealed a life-saving effect of NAC in a dose-dependent manner with reduction of in-hospital mortality for the NAC high-dose group, but not for the NAC standard-dose (<3500-mg) group. In conclusion, without being able to conclude on the nature of the mechanism involved, our review suggests a benefit of NAC in cardiovascular-risk patients in perioperative period in terms of mortality and supports prospective confirmatory studies.

27 November 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
FSFlorimond Suard
Florimond Suard
MMMartin Mombrun
Martin Mombrun
MFMarc‐Olivier Fischer
Marc‐Olivier Fischer
JHJean‐Luc Hanouz
Jean‐Luc Hanouz
JDJean‐Baptiste Decros
Jean‐Baptiste Decros
RDRichard Descamps
Richard Descamps